



6 August 2020

Sydney, Australia

Noxopharm Extraordinary General Meeting Reminder

Sydney, 6 August 2020: Noxopharm (ASX: NOX) wishes to remind shareholders that an Extraordinary General Meeting is scheduled to take place on Friday, 14 August 2020 at 10:30am (AEST).

The purpose of the meeting is to seek shareholder approval for a number of resolutions relating to the recent non-renounceable rights issue.

The Company also will take the opportunity to provide an update on recent progress in its R&D activities and plans for upcoming clinical trials that were the subject of the recent capital raise. A corporate presentation will be lodged with the ASX before the meeting and the CEO (Dr Graham Kelly) and CMO (Dr Gisela Mautner) will present the update virtually.

Details of the meeting are set out in the Notice of Meeting as lodged with ASX on 14 July 2020.

<https://www.asx.com.au/asxpdf/20200714/pdf/44kh156zkmpc7v.pdf>

Virtual meeting

Noxopharm wishes to remind shareholders that due to the significant health concerns attributed to the Covid-19 pandemic, in addition to guidelines and restrictions issued by Australian state and federal governments, shareholders are encouraged to attend the meeting virtually (which will be broadcast as a live webinar). Please **pre-register** in advance for the virtual meeting here:

https://us02web.zoom.us/webinar/register/WN_YicKa8P-Spq4_3rR2I8HvA

After registering, you will receive a confirmation containing information on how to attend the virtual meeting.

Shareholders will be able to vote and ask questions at the virtual meeting. Shareholders also are encouraged to submit questions in advance of the Extraordinary General Meeting to the Company. Questions must be submitted in writing to David Franks, Company Secretary, at David.Franks@automicgroup.com.au at least 48 hours before the Extraordinary General Meeting.

Voting by proxy

Shareholders who wish to participate and vote at the EGM are strongly encouraged to complete and submit their proxies as early as possible.

To vote by proxy, please use one of the following methods:

| | |
|---------------|---|
| Online | Lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the instructions: Log into the Automic website using the holding details as shown on the Proxy Form. Click on 'View Meetings' – 'Vote'. To use the online |
|---------------|---|



| | |
|----------------|---|
| | lodgement facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown on the front of the Proxy Form. |
| By post | Automatic, GPO Box 5193, Sydney NSW 2001 |
| By hand | Automatic, Level 5, 126 Phillip Street, Sydney NSW 2000 |

Your Proxy instruction must be received not later than 48 hours before the commencement of the Meeting. **Proxy Forms received later than this time will be invalid.**

The Chair intends to vote all open proxies in favour of all resolutions, where permitted.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body's immune system to inflict damage on cancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).

To learn more please visit: <https://www.noxopharm.com/>

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automaticgroup.com.au

Media Enquiries

Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Graham Kelly, CEO and Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may",



“plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.